{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Protocol amendment summary of changes table', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Clinical trial summary', 'The clinical trial summary was edited to reflect changes to the', 'protocol.', 'Section 8.2,', 'The possibility to use an IV H1 antagonist other than', 'Lack of availability of IV', 'Noninvestigational', 'diphenhydramine or an oral formulation, if no H1 antagonist IV', 'diphenhydramine in some', 'medicinal products', 'formulation is available, at an appropriate dosing, is offered.', 'countries', 'AMENDMENT FOR FRANCE:', 'Amendment 06 FR: 21-May-2018', 'This protocol amendment (Amendment 05 FR) is considered to be nonsubstantial based on the', 'criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the', 'Council of the European Union [because it neither significantly impacts the safety or', 'physical/mental integrity of participants nor the scientific value of the study].', 'Overall Rationale for the Amendment', 'The primary driver for this amendment was to make an H1 antagonist other than intravenous (IV)', 'diphenhydramine available in countries where IV diphenhydramine is not available.', 'Protocol amendment summary of changes table', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Clinical trial summary', 'The clinical trial summary was edited to reflect changes to the', 'protocol.', 'Section 8.2,', 'The possibility to use an IV H1 antagonist other than', 'Lack of availability of IV', 'Noninvestigational', 'diphenhydramine or an oral formulation, if no H1 antagonist IV', 'diphenhydramine in some', 'medicinal products', 'formulation is available, at an appropriate dosing, is offered.', 'countries', 'Property of the Sanofi Group - strictly confidential', 'Page 140', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix I Protocol amendment history', 'The Protocol Amendment Summary of Changes Table for the current amendment is located', 'directly after the title page.', 'Amended protocol 04 (09 Mar 2020)', 'In Europe, this amended protocol 04 is considered to be substantial based on the criteria set forth', 'in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the', 'European Union because it significantly impacts the safety or physical/mental integrity of', 'participants.', 'OVERALL RATIONALE FOR THE AMENDMENT', 'The amendment provides additional updates and safety measures based on safety concerns that', 'have been identified from post-marketing use of alemtuzumab in adults. Updates include', 'additional safety measures, contraindications and adverse events of special interest (AESIs)', 'important for patient safety. Details of updates are outlined below.', 'Protocol amendment summary of changes table', 'Section No. and name', 'Description of change', 'Brief rationale', 'Clinical trial summary', 'Added a note in the exclusion criteria with following text:', 'Update of safety', 'And', 'information following', 'Section 7.2 Exclusion criteria', 'NOTE: Prior to initiation of any alemtuzumab treatment course,', 'Pharmacovigilance', 'Risk Assessment', 'contraindications should be reviewed as pre-treatment verification of', 'Comittee (PRAC)', 'eligibility.', 'recommendations', 'during the EU Article', '20 Procedure.', 'Section 1.2.1 Schedule of', \"Added additional footnote 'V' in flow chart 1.2.1 part 1 (year 1) with\", 'Update of the safety', 'events Part 1 (Year 1)', 'below text:', 'information following', 'Contraindications, including the following must be checked before', 'the PRAC', 'infusion: severe active infection, uncontrolled hypertension, history of', 'recommendations', 'arterial dissection of the cervicocephalic arteries, history of stroke,', 'history of angina pectoris or myocardial infarction, known', 'coagulopathy or on concomitant anti-coagulant therapy', 'Section 4 Introduction and', 'In sub-section \"Alemtuzumab Post-Marketing Updates in Adult\",', 'Update based on adult', 'Rationale', 'added \"temporally associated\" before \"pulmonary alveolar', 'post-marketing data', 'haemorrhage, myocardial ischemia.', 'In sub-section \"Alemtuzumab Post-Marketing Updates in Adult\",', 'added acquired hemophilia A and PML in Post-marketing PV', 'monitoring identified events', 'Section 8.6 Storage', 'LEMTRADA has been replaced by alemtuzumab.', 'Administrative change', 'Conditions and Shelf Life', 'And', 'Section 10.1.4 Visit 4/M0/D1', '(first course of', 'alemtuzumab)', 'Property of the Sanofi Group - strictly confidential', 'Page 141', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}